共 167 条
[1]
Cortazar P(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 164-172
[2]
Zhang L(2015)Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 Ann. Oncol. 26 1533-1546
[3]
Untch M(2015)Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann. Oncol. 26 v8-v30
[4]
Mehta K(2016)Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis JAMA Oncol. 2 1477-1486
[5]
Costantino JP(2008)Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics J. Natl. Cancer Inst. 100 1380-1388
[6]
Wolmark N(2016)Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: results of the UNICANCER CARMINA 02 French trial (UCBG 0609) Cancer 122 3032-3040
[7]
Coates AS(2007)Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer J. Natl. Cancer Inst. 99 167-170
[8]
Winer EP(2005)Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer—a study from the IMPACT trialists J. Clin. Oncol. 23 2477-2492
[9]
Goldhirsch A(2001)Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study Ann. Oncol. 12 1527-1532
[10]
Gelber RD(2015)Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer Br. J. Cancer 113 585-594